Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.97
-0.02 (-0.33%)
At close: Apr 28, 2026, 4:00 PM EDT
5.97
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Ardelyx Employees
Ardelyx had 489 employees as of December 31, 2025. The number of employees increased by 94 or 23.80% compared to the previous year.
Employees
489
Change (1Y)
94
Growth (1Y)
23.80%
Revenue / Employee
$832,965
Profits / Employee
-$125,969
Market Cap
1.46B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Immatics | 711 |
| Agios Pharmaceuticals | 540 |
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Biohaven | 274 |
| Precigen | 160 |
| Maze Therapeutics | 141 |
ARDX News
- 1 day ago - Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings - GlobeNewsWire
- 5 days ago - Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026 - GlobeNewsWire
- 8 days ago - Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer - GlobeNewsWire
- 12 days ago - Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026 - GlobeNewsWire
- 27 days ago - Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx - GlobeNewsWire
- 6 weeks ago - Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award - GlobeNewsWire
- 7 weeks ago - Ardelyx Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C - GlobeNewsWire